180.15 USD
-1.23 (-0.68%)
180.15 USD
0 (0%)
Taking everything into account, ICLR scores 5 out of 10 in our fundamental rating. ICLR was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ICLR get a neutral evaluation. Nothing too spectacular is happening here. ICLR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ICLR was profitable.
In the past year ICLR had a positive cash flow from operations.
Each year in the past 5 years ICLR has been profitable.
Each year in the past 5 years ICLR had a positive operating cash flow.
1.2 Ratios
ICLR has a better Return On Assets (3.63%) than 75.44% of its industry peers.
ICLR has a Return On Equity of 6.42%. This is in the better half of the industry: ICLR outperforms 75.44% of its industry peers.
The Return On Invested Capital of ICLR (6.74%) is better than 75.44% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 13.75%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.74%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROIC | 6.74% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
1.3 Margins
With a decent Profit Margin value of 7.40%, ICLR is doing good in the industry, outperforming 75.44% of the companies in the same industry.
In the last couple of years the Profit Margin of ICLR has declined.
ICLR has a better Operating Margin (13.99%) than 73.68% of its industry peers.
ICLR's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 28.15%, ICLR is doing worse than 77.19% of the companies in the same industry.
ICLR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% |
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICLR is destroying value.
The number of shares outstanding for ICLR has been reduced compared to 1 year ago.
Compared to 5 years ago, ICLR has more shares outstanding
The debt/assets ratio for ICLR has been reduced compared to a year ago.
2.2 Solvency
ICLR has an Altman-Z score of 2.09. This is not the best score and indicates that ICLR is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.09, ICLR is in line with its industry, outperforming 49.12% of the companies in the same industry.
ICLR has a debt to FCF ratio of 3.53. This is a good value and a sign of high solvency as ICLR would need 3.53 years to pay back of all of its debts.
ICLR has a better Debt to FCF ratio (3.53) than 78.95% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ICLR is not too dependend on debt financing.
ICLR has a Debt to Equity ratio (0.31) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Altman-Z | 2.09 |
ROIC/WACC0.76
WACC8.88%
2.3 Liquidity
A Current Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
With a Current ratio value of 1.06, ICLR is not doing good in the industry: 84.21% of the companies in the same industry are doing better.
ICLR has a Quick Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.06, ICLR is doing worse than 77.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
The Earnings Per Share has been growing by 15.23% on average over the past years. This is quite good.
The Revenue has decreased by -2.46% in the past year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
3.2 Future
ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.27% yearly.
Based on estimates for the next years, ICLR will show a small growth in Revenue. The Revenue will grow by 2.38% on average per year.
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.27%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ICLR is valuated correctly with a Price/Earnings ratio of 13.66.
Based on the Price/Earnings ratio, ICLR is valued cheaper than 96.49% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.25. ICLR is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 13.20, the valuation of ICLR can be described as correct.
Based on the Price/Forward Earnings ratio, ICLR is valued cheaply inside the industry as 98.25% of the companies are valued more expensively.
ICLR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.66 | ||
| Fwd PE | 13.2 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICLR is valued cheaper than 98.25% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ICLR is valued cheaply inside the industry as 96.49% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.27 | ||
| EV/EBITDA | 11.03 |
4.3 Compensation for Growth
ICLR has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.9
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
5. Dividend
5.1 Amount
ICLR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
180.15
-1.23 (-0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.53%
Inst Owner Change-0.01%
Ins Owners0.66%
Ins Owner ChangeN/A
Market Cap13.76B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts75
Price Target209.67 (16.39%)
Short Float %3.68%
Short Ratio2.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-0.06%
PT rev (3m)-4.74%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-1.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.66 | ||
| Fwd PE | 13.2 | ||
| P/S | 1.7 | ||
| P/FCF | 14.27 | ||
| P/OCF | 12.06 | ||
| P/B | 1.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.03 |
EPS(TTM)13.19
EY7.32%
EPS(NY)13.65
Fwd EY7.58%
FCF(TTM)12.63
FCFY7.01%
OCF(TTM)14.93
OCFY8.29%
SpS106.11
BVpS122.25
TBVpS-38.98
PEG (NY)N/A
PEG (5Y)0.9
Graham Number190.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 6.98% | ||
| ROICexgc | 176.34% | ||
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% | ||
| FCFM | 11.9% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 45.31% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.92% | ||
| Profit Quality | 160.84% | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 2.09 |
F-Score6
WACC8.88%
ROIC/WACC0.76
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.27%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.2%
EBIT Next 3Y1.96%
EBIT Next 5Y4.34%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%
ICON PLC / ICLR FAQ
Can you provide the ChartMill fundamental rating for ICON PLC?
ChartMill assigns a fundamental rating of 5 / 10 to ICLR.
What is the valuation status for ICLR stock?
ChartMill assigns a valuation rating of 6 / 10 to ICON PLC (ICLR). This can be considered as Fairly Valued.
How profitable is ICON PLC (ICLR) stock?
ICON PLC (ICLR) has a profitability rating of 6 / 10.
What is the valuation of ICON PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ICON PLC (ICLR) is 13.66 and the Price/Book (PB) ratio is 1.47.
How financially healthy is ICON PLC?
The financial health rating of ICON PLC (ICLR) is 5 / 10.